BNP Paribas Financial Markets Sells 258,120 Shares of QIAGEN N.V. $QGEN

Key Points

• BNP Paribas Financial Markets reduced its stake in Qiagen N.V. by 17.1%, selling 258,120 shares, which leaves them with approximately 1,251,587 shares valued at $50.25 million.
• Several institutional investors, including Wellington Management Group and Deutsche Bank AG, increased their investments in Qiagen, with Deutsche Bank boosting its holdings by 57.5%.
• Qiagen reported a quarterly earnings per share (EPS) of $0.60, aligning with analyst expectations, and recorded a 7.7% increase in revenue year-over-year.

BNP Paribas Financial Markets lowered its stake in QIAGEN N.V. (NYSE:QGEN - Free Report) by 17.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,251,587 shares of the company's stock after selling 258,120 shares during the period. BNP Paribas Financial Markets owned approximately 0.56% of QIAGEN worth $50,251,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in shares of QIAGEN by 12.2% in the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after buying an additional 2,656,136 shares during the period. Deutsche Bank AG increased its holdings in shares of QIAGEN by 57.5% in the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after buying an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of QIAGEN by 3,030.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock worth $179,501,000 after buying an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in QIAGEN by 4.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock valued at $96,605,000 after purchasing an additional 109,481 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in QIAGEN during the 4th quarter valued at approximately $95,746,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

QIAGEN Stock Down 0.5%

Shares of QGEN traded down $0.24 on Wednesday, reaching $46.68. The stock had a trading volume of 1,931,178 shares, compared to its average volume of 1,441,401. The firm has a market capitalization of $10.38 billion, a price-to-earnings ratio of 27.58, a price-to-earnings-growth ratio of 2.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The company has a 50-day simple moving average of $48.68 and a 200-day simple moving average of $44.25. QIAGEN N.V. has a 12-month low of $37.63 and a 12-month high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same quarter last year, the business posted $0.55 EPS. The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts predict that QIAGEN N.V. will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Barclays assumed coverage on QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective on the stock. Bank of America lifted their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. UBS Group lifted their price objective on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Finally, Cowen reiterated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.